Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the ...

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

Administered intravenously, the monoclonal antibody MK-2060 has a "novel approach" to anticoagulation by blocking the ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Huntington’s disease affects an estimated 5 to 10 per 100,000 people in most Western countries, with variation by region and ...